Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematological Malignancy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SRSF2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SRSF2 (WT & P95H Mutant) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spec. Optimized for RNA-binding assays. |
View SRSF2 Products |
| Gene Delivery | SRSF2 Promise-ORF / Lentivirus Full-length WT and P95H mutant ORF for stable cell line generation. |
View SRSF2 Products |
| Benchmark Ab | Anti-SRSF2 Recombinant Antibody Validated positive control for Western Blot and Immunoprecipitation. |
View SRSF2 Products |
| Validator | SRSF2 siRNA Set For knockdown verification in target validation assays. |
View SRSF2 Products |
| Related Target A | SF3B1 Core splicing factor frequently co-mutated or synergistically targeted in myelodysplastic syndromes (MDS). |
View SF3B1 Products |
| Related Target B | U2AF1 U2 auxiliary factor gene mutated in myeloid neoplasms, sharing similar therapeutic intervention strategies. |
View U2AF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Solubility and aggregation of RS-domain containing proteins | Domain-optimized constructs (RRM + Linker) with solubility-enhancing tags, sequence verified. |
| WT vs Mutant (P95H) selectivity screening | Paired Wild-Type and P95H Mutant proteins produced under identical expression conditions for comparative binding assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control expression vectors. |
| False Positives | Validated siRNA pool included for target knockdown and specificity confirmation. |
Live SRSF2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of RNA splicing machinery has emerged as a major frontier in oncology, particularly in myeloid malignancies such as Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). SRSF2 (Serine/Arginine-Rich Splicing Factor 2) mutations, predominantly occurring at the Proline 95 (P95) hotspot, alter RNA-binding specificity rather than causing a simple loss of function. This neomorphic activity leads to massive mis-splicing of critical hematopoietic regulators.
The race for SRSF2 therapeutics is intensifying, with major players shifting focus from traditional cytotoxic splicing inhibitors to selective small molecule modulators, molecular glues, and synthetic lethal approaches. As first-generation splicing modulators (such as SF3B1 inhibitors) reach advanced clinical phases, the next wave of R&D is targeting SRSF2-mutant cells directly by exploiting downstream vulnerabilities or utilizing degrader technologies (PROTACs) to selectively eliminate the mutant splicing complex.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Modulators | H3 Biomedicine (Eisai), H3B-8800 | MDS, AML, CMML | In vitro RNA-binding assays (Need high-purity WT/Mutant SRSF2 proteins) |
| Molecular Glues / Degraders | Arvinas, Monte Rosa Therapeutics | Hematological Malignancies | Ternary complex formation assays (Need robust recombinant SRSF2 target proteins) |
| Antisense Oligonucleotides (ASO) | Ionis Pharmaceuticals | Splicing-mutant cancers | Cell-based splicing reporter assays (Need Lentivirus for stable cell line generation) |